BACKGROUND: Therapy-related myelodysplastic syndrome (t-MDS) and acute myeloid leukemia (t-AML) carry a poor prognosis. We analyzed the results of allogeneic HSCT in 38 children to determine which factors, if any, affected outcome. PROCEDURE: The effects of demographic, donor, and disease-related factors were analyzed to determine their effects on overall and disease-free survival (OS, DFS), relapse, and non-relapse mortality (NRM). RESULTS: OS and DFS for t-AML and t-MDS were similar. Three-year OS and EFS were the same (15.4 +/- 5.8%) and the 3-year NRM was 59.6 +/- 8.4%. The 1-year cumulative risk of grade III-IV acute graft-versus-host disease (GVHD) and relapse were 23.7 +/- 7.0% and 18.7 +/- 6.5%, respectively. The percentage of pre-transplant bone marrow (BM) blasts was positively associated with relapse (P = 0.05), while the percentage of BM blasts at diagnosis of therapy-related disease tended to associate with NRM (P = 0.07). Alternative donor and matched sibling donor grafts had similar outcomes. NRM was higher among patients who did not develop acute GVHD as compared to those with grade 1-2 acute GVHD (69.2 +/- 14.2% vs. +/- 12.7%, respectively), while NRM was 100% in patients with grade III-IV acute GVHD (P = 0.007). CONCLUSIONS: The percentage of BM blasts is associated with relapse in these disorders. High rates of NRM negatively impact the outcome of allogeneic HSCT for children with t-AML and t-MDS. Future studies should focus on reducing NRM.
BACKGROUND: Therapy-related myelodysplastic syndrome (t-MDS) and acute myeloid leukemia (t-AML) carry a poor prognosis. We analyzed the results of allogeneic HSCT in 38 children to determine which factors, if any, affected outcome. PROCEDURE: The effects of demographic, donor, and disease-related factors were analyzed to determine their effects on overall and disease-free survival (OS, DFS), relapse, and non-relapse mortality (NRM). RESULTS: OS and DFS for t-AML and t-MDS were similar. Three-year OS and EFS were the same (15.4 +/- 5.8%) and the 3-year NRM was 59.6 +/- 8.4%. The 1-year cumulative risk of grade III-IV acute graft-versus-host disease (GVHD) and relapse were 23.7 +/- 7.0% and 18.7 +/- 6.5%, respectively. The percentage of pre-transplant bone marrow (BM) blasts was positively associated with relapse (P = 0.05), while the percentage of BM blasts at diagnosis of therapy-related disease tended to associate with NRM (P = 0.07). Alternative donor and matched sibling donor grafts had similar outcomes. NRM was higher among patients who did not develop acute GVHD as compared to those with grade 1-2 acute GVHD (69.2 +/- 14.2% vs. +/- 12.7%, respectively), while NRM was 100% in patients with grade III-IV acute GVHD (P = 0.007). CONCLUSIONS: The percentage of BM blasts is associated with relapse in these disorders. High rates of NRM negatively impact the outcome of allogeneic HSCT for children with t-AML and t-MDS. Future studies should focus on reducing NRM.
Authors: Wing Keung Chan; May Kung Sutherland; Ying Li; Jonathan Zalevsky; Sarah Schell; Wing Leung Journal: Clin Cancer Res Date: 2012-09-26 Impact factor: 12.531
Authors: Akshay Sharma; Sujuan Huang; Ying Li; Russell J Brooke; Ibrahim Ahmed; Heather B Allewelt; Persis Amrolia; Alice Bertaina; Neel S Bhatt; Marc B Bierings; Joshua Bies; Claire Brisset; Jennifer E Brondon; Ann Dahlberg; Jean-Hugues Dalle; Hesham Eissa; Mony Fahd; Adam Gassas; Nicholas J Gloude; W Scott Goebel; Erika S Goeckerman; Katherine Harris; Richard Ho; Michelle P Hudspeth; Jeffrey S Huo; David Jacobsohn; Kimberly A Kasow; Emmanuel Katsanis; Saara Kaviany; Amy K Keating; Nancy A Kernan; Yiouli P Ktena; Colette R Lauhan; Gerardo López-Hernandez; Paul L Martin; Kasiani C Myers; Swati Naik; Alberto Olaya-Vargas; Toshihiro Onishi; Mohamed Radhi; Shanti Ramachandran; Kristie Ramos; Hemalatha G Rangarajan; Philip A Roehrs; Megan E Sampson; Peter J Shaw; Jodi L Skiles; Katherine Somers; Heather J Symons; Marie de Tersant; Allison N Uber; Birgitta Versluys; Cheng Cheng; Brandon M Triplett Journal: Bone Marrow Transplant Date: 2021-09-03 Impact factor: 5.174
Authors: Reinhard Stauder; Friedrich Wimazal; Thomas Nösslinger; Otto Krieger; Wolfgang R Sperr; Heinz Sill; Michael Pfeilstöcker; Peter Valent Journal: Wien Klin Wochenschr Date: 2008 Impact factor: 1.704
Authors: Angela R Smith; Ellen C Christiansen; John E Wagner; Qing Cao; Margaret L MacMillan; Heather E Stefanski; Barbara A Trotz; Michael J Burke; Michael R Verneris Journal: Pediatr Blood Cancer Date: 2012-11-14 Impact factor: 3.167